Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

ABSTRACT: Despite advances in the development of highly effective androgen receptor (AR)-directed therapies for the treatment of men with advanced prostate cancer, acquired resistance to such therapies frequently ensues. A significant subset of patients with resistant disease develop AR-negative tumors that lose their luminal identity and display neuroendocrine features (neuroendocrine prostate cancer (NEPC)). The cellular heterogeneity and the molecular evolution during the progression from AR-positive adenocarcinoma to AR-negative NEPC has yet to be characterized. Utilizing a new genetically engineered mouse model, we have characterized the synergy between Rb1 loss and MYCN (encodes N-Myc) overexpression which results in the formation of AR-negative, poorly differentiated tumors with high metastat

SUBMITTER: Brady NJ 

PROVIDER: S-EPMC8185096 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature